Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in adults 18+ with data read-outs expected H2 2024 PHILADELPHIA / Jun 07, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) today... Read More